Linked Life Data

16458417

Source:http://linkedlifedata.com/resource/pubmed/id/16458417

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2006-4-17
pubmed:abstractText
Progression of hormone-refractory prostate cancer (HRPC) is associated with skeletal complications and bone pain, which contribute to deterioration in quality of life (QOL). The effects of new HRPC therapies on patients' QOL need to be studied. Patient-based assessments that help quantify the risk-benefit profile of HRPC therapies are warranted. This review summarizes the known QOL literature and estimates the potential effect of atrasentan, a novel, selective endothelin A receptor antagonist (SERA), on the QOL of HRPC patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0302-2838
pubmed:author
pubmed:issnType
Print
pubmed:volume
49
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
781-9
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
pubmed:affiliation
Northwestern University, Chicago, Illinois 60201, USA. d-cella@northwestern.edu
pubmed:publicationType
Journal Article, Review